AbbVie Posts More Positive Hep-C Results, ENTA Jumps
Insights - Last month, AbbVie (ABBV) reported that its new Hepatitis-C treatment was effective in 96% of patients who had never been treated for the virus. On … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
This CNS Drug Developer is Getting Interesting
Insights - -Buy near recent financing price. Stock is attractive into year-end, but more importantly, could be a top biotech play in 2014. Note that stock is relatively … Continue Reading
Premium
The Turnaround Begins: Icahn Backs Hologic Board & Management
Insights - In two press releases on Monday morning, Hologic (HOLX) announced the hiring of a new CEO and the addition of two new independent members to … Continue Reading
Premium
The Annual Meeting of the American Society of Hematology in Brief
Insights - This week’s Annual Meeting of the American Society of Hematology (ASH) will highlight new treatments, new indications, new pathways and new ways of engineering cancer-treating … Continue Reading
Read nowBiotech Recap: Our Top Stories from the Week
Insights - Last week we introduced a new look for PropThink.com and launched a more affordable option for PropThink readers interested in exploring our Premium content. Not to worry, we’ll still … Continue Reading
Read now
Data Support New Indications for Theravance and Glaxo in Asthma
Insights - GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) posted positive results from a phase 3 study of its combination drug, Ellipta (FF/VI), as an asthma medication. The … Continue Reading
Read now
Novartis Myeloma Drug Shows Early Promise in Key Trial
Insights - An experimental drug from Novartis (NVS) designed to treat a bone marrow cancer met its primary goal in a phase 3 study. In an earlier … Continue Reading
Read now